The Needle-Free Injections market is increasing owing to the prevalence of chronic diseases, expanding the number of needle-stick injuries, the rising patient awareness regarding the ease-of-use of Needle-Free Injections, and the technologically advanced products.
LAS VEGAS, Dec. 6, 2021 /PRNewswire/ — DelveInsight launched a new report on "Needle-Free Injections Market & Competitive Landscape," providing in-depth market understanding for Needle-Free Injections, which will further benefit the competitors or stakeholders operating in the Needle-Free Injections arena.
Recent Developmental Activities in Needle-Free Injections Market
In August 2021, PharmaJet and their partner Zydus Cadila announced the emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D, the world's first Plasmid DNA Vaccine for COVID-19. The vaccine- ZyCoV-D is exclusively administered by deploying the PharmaJet Tropis® Needle-free Injection System.
In October 2020, PharmaJet's Needleless vaccine injector was chosen to deliver one of the COVID-19 vaccines- the University of Cambridge's phase 1 trial of DIOSynVax's candidate. The trial will test the delivery of the vaccine through the skin without using needles.
Interested in knowing how the Needle-Free Injections Market will be growing by 2026? Click to get a snapshot of Needle-Free Injections Market Analysis.
Needle-Free Injections Overview
Needle-free injection technology (NFIT) is a tremendously broad notion that comprises a wide range of drug delivery systems that delivers drugs through the skin by any of the forces such as Lorentz, Shock waves, pressure by gas or electrophoresis, which forces the drug through the skin, almost abolishing the use of a hypodermic needle.
This is beneficial for the pharmaceutical industry, and developing countries find it extremely valuable in mass immunisation programs, avoiding the chances of needle stick injuries and other complications, including those arising due to multiple uses of a single needle. These devices can be categorised based on their working, type of load, mechanism of drug delivery and site of delivery.
According to the World Health Organization (WHO) 2021, in 2019, the number of individuals affected with diabetes has increased drastically from 108 million in 1980 to 422 million in 2014. According to the data provided by the International Diabetes Federation (IDF) Diabetes Atlas Ninth Edition 2019, there were approximately 463 million adults in the age group 20-79 years and is expected to reach 700 million by 2045.
Geography-Wise Needle-Free Injections Market Analysis
Geographically, the global Needle-Free Injections market is studied for North America, Europe, Asia-Pacific, and the Rest of the World. In terms of revenue share, North America is expected to account for the largest share in the needle-free injections market because of the high prevalence of chronic diseases, increase in the awareness regarding needle-free injections, improving disposable income, and better healthcare infrastructure along with the presence of major market players in the region among other factors in the region.
One of the key factors supporting the growth of the Needle-Free Injections market in the region is the high prevalence of diabetes. According to the Centers for Disease Control and Prevention 2021, almost 34 million people in the United States have diabetes, with 90-95% of them having type 2 diabetes. Therefore, an increase in the prevalence rate of the diabetes suffering population will lead to a greater demand for Needle-Free Injections in the market, further elevating the market growth.
Furthermore, the growing collaborations between the needle-free injection devices manufacturers and pharmaceutical companies in the region are further driving the needle-free injections market in the United States, and therefore in North America.
To know more why North America is leading the market growth in the Needle-Free Injections market, get a snapshot of Needle-Free Injections market report
There are great opportunities for Needle-Free Injections market penetration for countries like China, India, and Japan as the prevalence rate is high. According to the IDF Diabetes Atlas 9th Edition, an estimated 87.6 million adults aged 20-79 years were living with diabetes in the South-East Asia region in 2019, representing a regional prevalence of 8.8%. This is expected to increase to 153 million by 2045. It is estimated that around 60% of diabetics in the world live in Asia.
Covid-19 Impact on Needle-Free Injections Market
The demand for Needle-Free Injections is primarily affected by the outbreak of the COVID-19 pandemic because of the delay in the supply and manufacturing of the products. However, Type 2 diabetes, hypertension, and cardiovascular diseases have been identified as the most common comorbidities for SARS-CoV-2 infection and have been associated with worse outcomes and more severe courses of COVID-19. It was estimated that 10% of COVID-19 vaccine hesitancy maybe because of needle phobia, creating a demand for alternative delivery routes to clear a barrier to vaccination, such as Needle-Free Injections.
The demand for Needle-Free Injections was boosted by the approval of vaccines like Zydus' vaccine, which will be administered by needle-free injections in August 2021. In September 2021, Scancell advanced its effort to provide an alternative by tapping PharmaJet for needle-free delivery technologies. It is approved in South Africa to run a phase I clinical trial of the vaccine candidates in July, where the investigators will administer the vaccines using the PharmaJet Tropis and PharmaJet Stratis needle-free injection systems.
To discuss more the short/long-term impact of COVID-19 get a snapshot of the Needle-Free Injections market insight report
Needle-Free Injections Market Segmentation
By Product Type
Needle-Free Injections Market Segment Analysis
According to the estimates, in the product type segment of the Needle-Free Injections market, the application segment of the needle-free injections market, the insulin delivery needle-free injections are expected to account for the significant share in the market during the forecast period. Diabetics require multiple doses of insulin in a day, which can be a daunting process for patients in case of using conventional syringes and needles for insulin administration. These devices aid in the easy administration of insulin through the nozzle orifice, which results in the generation of a fine stream of insulin. Needle-free insulin injection systems offer the least resistant path for insulin administration, thereby facilitating the even spreading of insulin in the subcutaneous layer. Hence, the launch of new innovative products, various other factors such as user-friendly design, rising popularity, and adoption rate among the patient population are also anticipated to contribute to the Needle-Free Injections market growth.
Needle-Free Injections Market Scope
Study Period: 2018-2026
Key Companies: IntegriMedical LLC, INJEX Pharma GmbH, PharmaJet Corporation, CrossJect, European Pharma Group BV, National Medical Products Inc, Akra DermaJet, Meika Medical Co, Basco India., Mystic Pharmaceuticals Inc, Technologies Médicales Internationales (MIT Canada) Inc., INOVIO Pharmaceuticals, MADA MEDICAL PRODUCTS INC., Portal Instruments, D'Antonio Consultants International, Inc and others.
Analysis: The Needle-Free Injections market is expected to grow at a CAGR of 14.15% during the forecast period from 2021 to 2026 to reach 24.12 billion by 2026.
Table of Contents
Needle-Free Injections Report Introduction
Needle-Free Injections Market Executive Summary
2.1 Scope of the Study
2.2 Market at Glance
2.3 Competitive Assessment
2.4 Financial Benchmarking
Regulatory and Patent Analysis
1. The United States
5. The U.K.
Needle-Free Injections Market Key Factors Analysis
1. Needle-Free Injections Market Drivers
2. Needle-Free Injections Market Restraints and Challenges
3. Needle-Free Injections Market Opportunities
Needle-Free Injections Porter's Five Forces Analysis
5.1 Bargaining Power of Suppliers
5.2 Bargaining Power of Consumers
5.3 Threat of New Entrants
5.4 Threat of Substitutes
5.5 Competitive Rivalry
COVID-19 Impact Analysis on Needle-Free Injections Market
Needle-Free Injections Market layout
7.1 By Product Type
7.2 By Technology
7.3 By Usability
7.4 By Application
7.5 By End-user
7.6 By Geography
Needle-Free Injections Global Company Share Analysis – Key 3-5 Companies
Needle-Free Injections Company and Product Profiles
1. IntegriMedical LLC
2. INJEX Pharma GmbH
5. European Pharma Group BV
6. National Medical Products Inc
7. Akra DermaJet
8. Meika Medical CO.
9. Basco India
10. Mystic Pharmaceuticals Inc
11. Technologies Médicales Internationales (MIT Canada) Inc.
12. INOVIO Pharmaceuticals
13. Portal Instruments
14. MADA MEDICAL PRODUCTS INC
15. D'Antonio Consultants International, Inc
DelveInsight's Diabetes Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the market and Competitive Landscape analysis. Key players involved in this market are BD, Medtronic, Terumo Group, F Hoffmann-La Roche Ltd., BIGFOOT BIOMEDICAL, INC, Eli Lilly and Company, Novo Nordisk A/S and others.
Diabetes Pen Market & Competitive Landscape
DelveInsight's Diabetes Pen Market-Market Insights, Competitive Landscape and Market Forecast–2026 report delivers an in-depth understanding of the market and Competitive Landscape analysis. Key players involved in this market are BD, Medtronic, Terumo Group, F Hoffmann-La Roche Ltd., BIGFOOT BIOMEDICAL, INC, Eli Lilly and Company, Novo Nordisk A/S, and others.
Injectable Drug Delivery Devices Market & Competitive Landscape
DelveInsight's Injectable Drug Delivery Devices Market Insights, Competitive Landscape and Market Forecast–2026 report delivers an in-depth understanding of the market and Competitive Landscape analysis. Key players involved in this market Eli Lilly and Company, Biocon, Becton, Dickinson & Company, West Pharmaceutical Services, Inc., Johnson & Johnson, Antares Pharma, AbbVie Inc., Pfizer Inc., Mylan N.V., Vetter Pharma-Fertigung GmbH & Co.KG, Emperra GmbH, Gerresheimer AG, SCHOTT AG, Terumo Corporation and others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Business Consulting Services with a credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.
View original content:https://www.prnewswire.com/news-releases/needle-free-injections-market-is-growing-at-a-cagr-of-14-15-during-the-forecast-period-from-2021-to-2026-and-will-reach-usd-24-12–billion-by-2026—affirms-delveinsight-301437736.html
SOURCE DelveInsight Business Research, LLP
Yahoo Finance's Anjalee Khemlani details government officials' changes to international travel into the U.S. and the reported effectiveness of GSK-Vir's proposed drug on fighting the Omicron variant.
Dr. Peter Hotez, co-director of the Center for Vaccine Development at Texas Children’s Hospital and Dean of the National School of Tropical Medicine at Baylor College of Medicine, joins Yahoo Finance to discuss the White House's response to coronavirus.
Bright Path CEO Tony Quinone joins Yahoo Finance to discuss how the Build Back Better Plan will promote locally produced paharmaceutical drugs.
Delivering remarks at the White House on Monday, President Biden pushed for the Senate to pass Build Back Better, saying it will reduce the cost of prescription drugs.
COVID-19 hospitalizations have been at all-time highs in New Hampshire in recent days, hitting a new high of 433 Monday.
NBC5 In Depth: How hospitals are preparing for omicron variant with already-tight capacity
A state representative fed up with unvaccinated residents wants them to pay for their own medical bills if they end up hospitalized with COVID-19.
President Joe Biden called on the Senate to pass his sweeping social and environmental package, which contains provisions that would lower the cost of prescriptions drugs.
On Monday, New York City Mayor Bill de Blasio issued a new vaccine mandate for private sector employees. Millions of workers have until December 27 to get vaccinated. Dr. Soumi Eachempati, the co-founder and CEO of Cleared4, joins CBSN's Elaine Quijano to explain.
Pfizer says preliminary research shows that a booster dose of its existing COVID-19 vaccine raises effectiveness when battling the Omicron variant. CBS News' Laura Podesta joins "CBSN AM" with more.
President Joe Biden says his social agenda legislation will deliver tangible savings on prescription drugs for all Americans. Biden says one in four Americans who take prescription drugs struggle to afford them. (Dec. 6)
New testing regulations for travels coming into the U.S. began Monday, and New York City announced plans for a vaccine mandate for all private employers. Hospitals already filled with patients with the Delta variant are bracing for a potential new wave of cases. CBS News' Skyler Henry reports, and then ER physician Dr. Rob Davidson joins CBSN's Tanya Rivero to discuss the latest.
(Bloomberg) — A group of workers at an Activision Blizzard Inc. division supporting the Call of Duty franchise plan to call out of work Monday in protest of job cuts that took place last week. The move reflects a broader labor movement taking hold at the embattled video game publisher.Most Read from BloombergThe World’s Relentless Demand for Chips Turns Deadly in MalaysiaSand and Soldiers Mix as Troops Move In to Protect Cancun TouristsEven in the Metaverse, Not All Identities Are Created Equal
Crypto stocks were up as bitcoin prices recovered; Intel will list shares in its Mobileye self-driving-car unit.
The private equity firm has raised $750 million since launching last year.
About a year ago, AutoZone was touting a strong start to FY 2021, after a first quarter that had seen blistering sales numbers, comfortable profit margins, and increasingly visible signs of success in the company’s commercial business. Because AutoZone has once again posted big numbers, continuing a streak of strong performances that began with a jolt from federal stimulus checks and unemployment benefits early in the pandemic, and continued even after their effects wore off.
(Bloomberg) — Most Read from BloombergThe World’s Relentless Demand for Chips Turns Deadly in MalaysiaSand and Soldiers Mix as Troops Move In to Protect Cancun TouristsEven in the Metaverse, Not All Identities Are Created EqualThe $300 Billion Plan to Bring Green Power to China’s MegacitiesMeet the New Climate Refugee in Town: CoyotesStock exchanges in the Middle East’s commercial capital will soon operate Monday through Friday after the United Arab Emirates decided to align its work week with
(Bloomberg) — Intel Corp. plans to list shares of its Mobileye self-driving car business by the middle of next year, letting the chipmaker capitalize on its investment in a burgeoning industry. Most Read from BloombergThe World’s Relentless Demand for Chips Turns Deadly in MalaysiaSand and Soldiers Mix as Troops Move In to Protect Cancun TouristsEven in the Metaverse, Not All Identities Are Created EqualThe $300 Billion Plan to Bring Green Power to China’s MegacitiesMeet the New Climate Refugee
Alibaba stock climbed as it named a new chief financial officer and plans to restructure its massive e-commerce operations.
Visa said Wednesday that it would launch a crypto advisory services for its clients, in another sign that digital assets are becoming more mainstream. One of its surveys has shown that nearly 40% of crypto owners would be likely to switch their primary bank to one that offers crypto-related products. Visa (ticker: V) is targeting banks seeking to attract customers with crypto offerings, or retailers who want to find out more about the new assets.